Thermo Fisher Scientific has agreed to sell its microbiology business to European private equity firm Astorg. The deal is valued at approximately $1.075 billion, comprising a mix of cash and a $50 million seller note.
The divestiture includes Thermo Fisher’s portfolio of antimicrobial susceptibility testing (AST) and culture media solutions, which serve clinical, pharmaceutical, and food safety sectors.
The Dark Report noted last year that Thermo Fisher’s lab products and specialty diagnostics divisions were the world’s largest in vitro diagnostics (IVD) business by revenue.
Key transaction details
Highlights of the deal include the following, according to Thermo Fisher:
- Saleprice: $1.075 billion ($1.025 billion in cash plus a $50 million seller note).
- Business performance: Thermo Fisher’s microbiology unit generated $645 million in revenue in 2025.
- Segment impact: Microbiology was formerly part of the specialty diagnostics segment.
- Expected close: Second half of 2026, pending regulatory approvals.
Strategic rationale behind the deal
Thermo Fisher CEO Marc N. Casper cited "active management" of the company’s portfolio as the primary driver for the Astorg deal, noting that the sale frees up capital for deployment into higher-value shareholder initiatives.
For Astorg, the acquisition adds a significant diagnostics and food safety pillar to its healthcare and life sciences portfolio.
Yet another shift in the IVD market
The divestiture of Thermo Fisher’s microbiology unit to Astorg represents a significant reshuffling of the vendors clinical laboratories rely on for daily operations.
For lab directors and managers, the primary takeaway is a likely shift in the level of service and innovation dedicated to traditional microbiology. As these legacy product lines—including antimicrobial susceptibility testing and culture media—move from a massive, multi-faceted conglomerate to a more specialized, private equity-backed entity, labs may see a renewed focus on the specific needs of the microbiology department rather than having those needs compete for resources within a $45 billion organization.
In the broader in vitro diagnostics (IVD) market, this deal underscores a trend where global medtech leaders are refining their portfolios to prioritize high-growth molecular and digital technologies over mature, traditional testing segments.
This move suggests that while the industry is rapidly digitizing, the foundational tools of clinical microbiology remain vital, high-value assets. Lab professionals should watch for how this transition impacts long-term contract pricing and vendor support structures, as the new standalone entity seeks to establish its own identity and market share against remaining diagnostic giants.
